Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Haleon launched a share buyback programme of up to £330m on Friday, representing the remaining portion of the £500m allocated ...

Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth.

Cocoa extract supplementation among older adults had no effect overall on the occurrence of age-related macular degeneration ...

This year’s unexpected demand for European stocks is helping to drive the region’s largest wave of block sales this century, ...

Global IPO markets made steady gains in 2024, with IPO proceeds increasing compared to the previous year as the high interest ...

Pfizer sells entire Haleon stake for $3.24 billion Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Kotak Alternate Asset Managers have announced an investment of ₹1,050 crore in Tirupati Medicare Ltd, a contract development ...

GSK's main partner in the consumer health joint venture that became Haleon – Pfizer – holds the remaining 32% in the new company and has said that it will sell its stake now that the ...

Haleon said in a prospectus filed earlier this week that it could face "possible liabilities" connected with OTC Zantac, although it is in the midst of indemnity negotiations with GSK and Pfizer ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...